This list is an analysis based on recent market events. It's not an investment recommendation.
About
Emyria Limited is a biotechnology firm currently in the clinical stage, dedicated to creating therapies for medical conditions that lack effective treatments. The company's work primarily involves the development of cannabinoid-derived pharmaceuticals, alongside an initiative for discovering new MDMA-based drugs. Among its pipeline, EMD-RX5 is being explored for psychological distress and irritable bowel syndrome, while EMD-RX7 targets a variety of medical conditions. Established in 2018 and based in Leederville, Australia, the company adopted its current name, Emyria Limited, in September 2020, having previously operated as Emerald Clinics Limited.
The current price of Q84.F is €0.03 EUR — it has increased by +2% in the past 24 hours. Watch Emyria Limited stock price performance more closely on the chart.
What is Emyria Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Frankfurt Exchange exchange Emyria Limited stocks are traded under the ticker Q84.F.
What is Emyria Limited market cap?▼
Today Emyria Limited has the market capitalization of 20.57M
When is the next Emyria Limited earnings date?▼
Emyria Limited is going to release the next earnings report on March 4, 2027.
What is Emyria Limited revenue for the last year?▼
Emyria Limited revenue for the last year amounts to 2.4M EUR.
What is Emyria Limited net income for the last year?▼
Q84.F net income for the last year is -3.62M EUR.
How many employees does Emyria Limited have?▼
As of November 3, 2026, the company has 6 employees.
In which sector is Emyria Limited located?▼
Emyria Limited operates in the Health & Wellness sector.
When did Emyria Limited complete a stock split?▼
The last stock split for Emyria Limited was on September 12, 2025 with a ratio of 5:4.
Where is Emyria Limited headquartered?▼
Emyria Limited is headquartered in Subiaco, Australia.